Scientific Advisory Board
CSO of Saniona
Co-founder of Saniona
Susan E. Bates
Department of Medicine, Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, New York
Director, Translational Cancer Medicine, Columbia University College of Physicians and Surgeons
Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.
Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning one Phase II trial within metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.
Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.